Exciting progress in treating Alzheimer's disease

Switch for the chance to WIN a pair of amazing Apple AirPods

Switch energy supplier to save up to £447* a year and the chance to win a pair of amazing Apple AirPods (T&Cs apply)

in partnership with Banner uswitch

Looking to switch your business energy supplier? Click here

* Between 1 Jul 2018 and 31 Dec 2018, at least 10% of people who switched energy supplier for both gas & electricity with uSwitch saved £447 or more.

Scientists claim they have made "exciting" progress in preventing brain deficits related to Alzheimer's disease (AD).

Researchers from the University of California, San Francisco (UCSF) found that reducing the levels of the protein tau can prevent seizures and neurological deficits related to AD.

AD is the most common form of dementia and there is as yet no effective way of preventing it. It is thought that the build-up of amyloid-beta proteins (AB) in people's brains is the cause of AD.

In tests on mice genetically engineered to simulate AD, the research team discovered that when tau was removed their memory function was retained and they lived a normal life span.

When one of both copies of the tau gene were eliminated the cognitive and neuronal deficits in these mice were prevented. Mice with reduced tau levels were also resistant to epileptic seizures.

Lennart Mucke, director of the Gladstone Institute of Neurological Disease at UCSF, said that the findings showed "the most striking therapeutic effect I have ever seen in our disease models".

"A lot more work needs to be done, of course. But if this strategy also works in humans, it could enable a major leap forward in our ability to treat and prevent devastating neurological diseases," he added. "There is an urgent need for better treatments in this field, so it is really exciting to have identified such a promising approach."

Click here to run an energy price comparison, and see if you could be paying less for your gas and electricity.

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more